Elizabeth Burtally's blog posts
Our Trials Acceleration Programme – fast-tracking clinical benefits to patients
If we think a drug could save lives, we want to be able to test as quickly as possible whether it’s safe and works better than current treatments. Find out how our Trials Acceleration Programme is helping us achieve this.
RUNX genes and their role in blood cancer development
Professor James Neil – one of our researchers at The University of Glasgow – sheds light on how we may be able to reverse resistance to commonly used drugs in blood cancer treatment.
New Years Honours 2017 – leading Bloodwise scientists recognised in list
The Queen’s New Year’s Honours List recognises the achievements and service of extraordinary people across the United Kingdom. We were delighted to see some of our Bloodwise funded researchers on the list – find out more here.
Bloodwise researchers present exciting new research at international haematology
The biggest international haematology meeting took place at the weekend, and many of our Bloodwise researchers were there. Find out what they had to say.
Bloodwise researchers share findings at international haematology conference
The biggest international haematology meeting will take place this weekend. Find out what exciting Bloodwise research will be featured there.
Finding the right drug combination for chronic lymphocytic leukaemia patients
Professor Mark Cragg is searching for clues to how some current cancer drugs work, so we can identify the ideal drug combinations that deliver the best benefits for patients. Find out more about this exciting research here.